Literature DB >> 19481782

Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction.

Gillian A Gray1, Mark Patrizio, Lorcan Sherry, Alyson A Miller, Mohammed Malaki, Alison F Wallace, James M Leiper, Patrick Vallance.   

Abstract

Asymmetric dimethylarginine (ADMA) and N(G) monomethyl-L-arginine (L-NMMA) are endogenous inhibitors of nitric oxide synthases (NOS) and their local concentration is determined by the activity of dimethylarginine dimethylaminohydrolases (DDAHs). The current study in male Wistar rats was designed to immunolocalise DDAH I and II in relation to NOS and to investigate changes in distribution, activity and ADMA content in the acute period following myocardial infarction (MI) resulting from coronary artery ligation. Seven days after the coronary artery ligation, L-Arg and methylated arginine content, as well as DDAH activity were determined in homogenates of left ventricular (LV) infarct and border. The distribution of immunoreactive DDAH I, DDAH II, eNOS and iNOS were determined in sections of LV. In healthy hearts, DDAH I was absent, however, DDAH II was localized to endothelium and endocardium with a similar distribution to that of eNOS. Following MI, LV DDAH activity was increased (to 210+/-19% of control, P<0.05). Both DDAH I and DDAH II proteins were detected in peri-infarct cardiomyocytes, while DDAH II immunoreactivity was additionally localized to infiltrating inflammatory cells and blood vessels in the healing infarct. Both plasma and LV concentrations of the DDAH substrate, ADMA, were increased post-MI, although the ratio of Arg:ADMA was retained in the LV post-MI relative to sham operated controls. In conclusion, DDAH II has a distribution similar to eNOS in healthy myocardium. The increased levels and activity of DDAH I and DDAH II enzymes following myocardial infarction suggest a potential role for them in local protection of NOS enzymes from inhibition by methylated arginines during infarct healing. 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481782     DOI: 10.1016/j.acthis.2009.02.009

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  5 in total

1.  Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.

Authors:  Xinli Hu; Dorothee Atzler; Xin Xu; Ping Zhang; Haipeng Guo; Zhongbing Lu; John Fassett; Edzard Schwedhelm; Rainer H Böger; Robert J Bache; Yingjie Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-14       Impact factor: 8.311

2.  Cardiomyocyte and Vascular Smooth Muscle-Independent 11β-Hydroxysteroid Dehydrogenase 1 Amplifies Infarct Expansion, Hypertrophy, and the Development of Heart Failure After Myocardial Infarction in Male Mice.

Authors:  Christopher I White; Maurits A Jansen; Kieran McGregor; Katie J Mylonas; Rachel V Richardson; Adrian Thomson; Carmel M Moran; Jonathan R Seckl; Brian R Walker; Karen E Chapman; Gillian A Gray
Journal:  Endocrinology       Date:  2015-10-14       Impact factor: 4.736

3.  Exploring the role of dimethylarginine dimethylaminohydrolase-mediated reduction in tissue asymmetrical dimethylarginine levels in cardio-protective mechanism of ischaemic postconditioning in rats.

Authors:  Kamaldeep Kaur; Nirmal Singh; R K Dhawan
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

4.  Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.

Authors:  Clemens Lange; Freya Mowat; Haroon Sayed; Manjit Mehad; Lucie Duluc; Sophie Piper; Ulrich Luhmann; Manasi Nandi; Peter Kelly; Alexander Smith; Robin Ali; James Leiper; James Bainbridge
Journal:  Exp Eye Res       Date:  2016-05-12       Impact factor: 3.467

5.  miR-378a-3p inhibits ischemia/reperfusion-induced apoptosis in H9C2 cardiomyocytes by targeting TRIM55 via the DUSP1-JNK1/2 signaling pathway.

Authors:  Jiaying Tan; Jun Shen; Huigeng Zhu; Ye Gong; Hechen Zhu; Junping Li; Shan Lin; Gang Wu; Tao Sun
Journal:  Aging (Albany NY)       Date:  2020-05-28       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.